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Abstract: To determine the predictors of success for selective laser
trabeculoplasty (SLT) in normal tension glaucoma (NTG).
This prospective cohort study recruited subjects with unilateral or
bilateral NTG on medication. All subjects received a single session of
3608 SLT treatment. SLT success was defined as IOP reduction20% at
1-month. The following covariates were analyzed via univariate and
multivariate analyses: age; sex; lens status; presenting, pre-SLT,
and post-SLT IOP’s; number and type of medications; SLT shots
and energy; and pre-SLT investigations.
In 60 eyes of 32 subjects with NTG, there were 30 right eyes and 28
left eyes. The success rate of SLT was 61.7%. Using 3 types of anti-
glaucoma medications (coefficient¼2.2, OR¼ 0.1, P¼ 0.02) and a
thicker retinal nerve fiber layer thickness (coefficient¼0.04,
OR¼ 0.96, P¼ 0.04) were associated with failure (univariate analysis).
In multivariate analysis, a higher pre-SLT IOP (coefficient¼ 1.1,
OR¼ 3.1, P¼ 0.05) and a lower 1-week IOP (coefficient¼0.8,
OR¼ 0.5, P¼ 0.04) were associated with success.
SLT was successful in over 60% of treated NTG patients. A higher
pre-SLT IOP and a greater IOP reduction at 1-week post-SLT were
predictors of a successful outcome.
(Medicine 93(28):e236)
Abbreviations: ALT = argon laser trabeculoplasty, IOP =
intraocular pressure, NTG = normal tension glaucoma, RNFL =
retinal nerve fiber layer, SLT = selective laser trabeculoplasty.
INTRODUCTION
S elective laser trabeculoplasty (SLT) works just as well inIOP-lowering as anti-glaucoma medication and argon laseru, PhD, Jonathan CSEd,
. Lai, MD
While SLT is safe and almost free of permanent damages
to the trabecular meshwork and cornea,13 not everyone that is
being treated responds. Recently, in a series of 83 eyes, SLTwas
found to be effective in normal tension glaucoma (NTG),
lowering the IOP by an additional 20% from pre-SLT levels
with 27% less medication use at 6 months while maintaining a
30% reduction from baseline IOP.14
Much work has been done to identify the factors that
predict SLT success including: an absence of IOP-lowering
medication prior to laser15–17 and a higher pre-SLT IOP.18
Conflicting results have been reported for angle pigmenta-
tion,6,7 while other factors like diabetes, central corneal thick-
ness, lens status, and angle status were not found to influence
SLT success.19 There is limited information in the literature
investigating variables that predict SLT outcomes in NTG.
METHODS
This prospective cohort study sequentially recruited sub-
jects from the ophthalmology clinic of a university hospital,
Queen Mary Hospital, Hong Kong Special Administrative
Region, China, during September 2011 to September 2012.
The study included subjects with NTG currently on anti-glau-
coma medication. Subjects were excluded if they had pre-
existing corneal pathology or scars, previous ALT or SLT
treatment, or if they defaulted follow-up. A single session of
SLT was performed by a single surgeon (JWYL) using a Q-
switched Nd:YAG laser (Ellex SoloTM, Ellex Medical Pty. Ltd.,
Adelaide, SA, Australia), for 3608 in all patients with an initial
energy of 0.8mJ and titrated until bubble formation was just
visible. For those with bilateral disease, both eyes were treated
in the same laser session. In all treated eyes, a single drop of
brimonidine (Alphagan P, Allergan, Inc., Waco, TX) was
instilled immediately after SLT and a dexamethasone 0.1%
and neomycin 0.5% combination eye drop (Dexoptic-N by
Ashford Laboratories Pvt. Ltd., Santacruz (West), Mumbai,
India) was used twice daily for 1 day and was continued for
a few more days only if anterior chamber reaction was detected
during follow-up. Patients returned for follow-up on Day 1,
1 week, 1 month, and 3 months after SLT. Patients continued the
same anti-glaucoma drug regime for the first month after SLT
and medication was subsequently titrated to achieve individual
target pressures as per the recommendations from The Colla-
borative Normal Tension Glaucoma Study, aiming at a 30%
reduction from presenting IOP.20
The following parameters were recorded during the study:
age, sex, lens status (phakic or pseudophakic), presenting IOP
without medication, pre-SLT IOP, post-SLT Day 1 IOP, post-
SLT 1week IOP, number of anti-glaucomamedications, number
of SLT shots, average laser energy used, pre-SLTaverage retinalFL) via a Spectralis Optical Coherene
Visual Field Index on Humphrey Field
nstruments, Inc., Zeiss Humphrey, San
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Leandro, CA), pre-SLT endothelial cell count via a non-contact
specular microscopy (Noncon ROBO-CA by Konan Medical
USA, Inc., Irvine, CA), pre-SLT central corneal thickness via
videokeratography (Orbscan1 IIz by Bausch & Lomb, Roche-
ster, NY), pre-SLT Snellen visual acuity, pre-SLT spherical
equivalent via kerato-refractometer (Topcon KR-8900 by Top-
con Europe Medical B.V., Capelle a/d Ijssel, Netherlands), and
the type of anti-glaucoma eye drops used pre-SLT (B-blocker,
carbonic anhydrase inhibitor, prostaglandin analog, alpha ago-
nist, or pilocarpine). All IOP readings were measured via
Goldmann applanation tonometry by a single investigator
and trained optometrists measured all other ocular parameters.
This study adhered to the tenets of the Declaration of
Helsinki. Informed patient consent and approval by the Institu-
tional Review Board were obtained prior to study commence-
ment. The authors declare no financial or proprietary interests.
The study was conducted without funding.
Definition of Success
The definition of SLT success was determined as a 20% or
more reduction in IOP at 1 month after SLT as compared to the
pre-SLT IOP. The 1 month IOP was selected as all anti-
glaucoma medications were kept unchanged until 1 month after
SLT; after which, anti-glaucoma medications were titrated to
achieve individual target pressures so the IOP’s measured
beyond 1 month will not solely represent the efficacy of SLT.
Statistics
The association of the 24 covariates (Table 1) with SLT
success was analyzed in the NTG group using univariate logistic
analysis and multiple regression analysis were used. The high
collinearity among the covariates hindered the interpretation of
traditional multiple logistic regression. To overcome this, vari-
able selection by elastic net approach was first conducted to opt
out redundant covariates where the estimates of coefficients
equaled to zero prior to multiple regression analysis.
We performed both the univariate and multivariate
regression analysis for the following 3 datasets separately:
(1) both eyes, (2) right eyes only, and (3) left eyes only. We
found that the significant variables detected from the right and
left eyes were different, signifying that each eye has a unique
underlying distribution, which was different from the other side
eye. Furthermore, the analysis using data from both eyes was the
most comprehensive in including all variables that were sig-
nificant when using just the right or left eyes alone. Hence, we
adopted the methodology of including both eyes in the dataset as
this reveals all the possible significant variables.
Correlations were expressed in coefficients and odds ratio
(OR) and a P< 0.05 was considered as statistically significant.
All means were expressed as mean standard deviation.
RESULTS
In 60 eyes of 32 subjects with NTG, there were 30 right
eyes and 28 left eyes. Twenty-eight subjects received bilateral
SLT treatment. The mean age was 67.4 12.3 years.
The mean IOP at initial presentation prior to starting anti-
glaucoma medication was 17.4 2.7mm Hg. The pre-SLT IOP
was 16.0 2.1mm Hg while on 1.7 1.0 types of anti-glau-
coma eye drops. The mean average RNFL thickness was
Lee et al66.2 15.1mm.
The mean SLT shots applied was 185.4 27.5 per session
using a mean power of 1.0 0.08mJ. The mean IOP at 1 month
2 | www.md-journal.comafter SLT was 12.5 2.1mm Hg representing an IOP reduction
of 21.5 11.4%. The success rate of SLT (eyes with IOP
reduction 20%) was 61.7% (37/60).
Using univariate analysis, the following parameters were
significantly associated with SLT failure: using 3 anti-glaucoma
eye drops prior to SLT (coefficient¼2.2, OR¼ 0.1, P¼ 0.02)
and a thicker RNFL (coefficient¼0.04, OR¼ 0.96,
P¼ 0.04). In multivariate analysis, a higher pre-SLT IOP
(coefficient¼ 1.1, OR¼ 3.1, P¼ 0.05) and a lower 1-week
IOP (coefficient¼0.8, OR¼ 0.5, P¼ 0.04) were associated
with SLT success (Table 1).
DISCUSSION
Identification of factors that predict success is important
for SLT because not everyone that is being treated responds in
the same manner; the success rate for SLT in open angle
glaucoma ranges from 65% to 100%.3–12 We noted slightly
lower success rate (61.7%) than what has been reported in the
literature primarily because our population consisted of subjects
with normal/low IOP and as we have demonstrated in multi-
variate analysis that SLT success was correlated with a higher
pre-treatment IOP. This finding was consistent with other
reports that reported associations of higher IOP with SLT
success18 with OR in the range of 1.321 to 1.5822 for open
angle glaucomas. We report an OR of 3.1 when using a higher
pre-SLT IOP as a predictor of success.
A lower IOP in the earlier phase (1-week) following SLT
was also a significant predictor for success. This was consistent
with the findings of a larger series including primary open angle
glaucomas that reported a similar association with IOP 1 day
following SLT.23 A greater IOP reduction in the early periods
following SLT may represent a higher level of metalloprotei-
nases, cytokines, and macrophages, which have been proposed
to be the biological agents responsible for IOP-lowering.24
The results from our study suggest that the number of anti-
glaucoma medication use prior to SLT may influence its
success. It was found that using 3 types of anti-glaucoma
eye drops prior to SLT was associated with a higher failure
rate (P¼ 0.02). We postulate that those using multiple anti-
glaucoma medications were likely to have a lower pre-SLT IOP
hence, less success with SLT because of this indirect association
with pre-treatment IOP. The influence of medication on SLT
has been controversial. While some have suggested that SLT
response is better for those without prior medication use,15,16
others have reported no differences in outcome with anti-
glacoma medication use25 and it has even been suggested that
SLT may have an additive effect with anti-glaucoma medi-
cation.26 In a recent study on the predictors of SLT in Chinese
POAG, the use of a topical carbonic anhydrase inhibitor prior to
laser was found to be associated with greater success
(coefficient¼ 1.7; OR: 6.0; P¼ 0.003).27
A thicker average RNFL thickness was weakly associated
with a higher failure rate for SLT. This observation was
consistent with that of a larger series involving primary angle
open angle glaucomas, where it was postulated that those with a
higher IOP may present with more advanced RNFL thinning,
hence those with a thicker RNFL (less RNFL damage) may be
those with a lower or better IOP control and hence, poorer
response to SLT, another indirect association between pre-SLT
IOP and SLT response.
Medicine  Volume 93, Number 28, December 2014Our study was limited by the fact that the 1-month IOP was
used as a reference of SLT success, a longer time period
following SLT would have been more ideal. However, the
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1-month period was selected based on previous knowledge
that even the 2-week post-SLT IOP was already predictive of
future IOP control28 as well as to be compliant with the clinical
practice at our center of adjusting patients’ medication regimen
for those with suboptimal response to SLT at 1 month following
treatment. The results in this study were derived from a popu-
lation of medically treated NTG subjects that received adjuvant
SLT and may not be generalizable to naive eyes or those with
other forms of glaucoma.
To the best of our knowledge, this is one of the few and
more comprehensive analyses on the predictors of success in
NTG. In summary, SLT was successful in over 60% of NTG
patients. A higher pre-SLT IOP and a greater IOP reduction at 1-
week post-SLT were predictors of success while using 3 types
of anti-glaucoma eye drops and a thicker RNFL were associated
with SLT failure.
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